Serum Zinc Concentration and Sarcopenia: A Close Linkage in Chronic Liver Diseases.

We sought to investigate the influence of serum zinc (Zn) concentration on sarcopenia in chronic liver diseases (CLDs, = 372, median age = 65 years, 147 liver cirrhosis (LC) cases (39.5%)). Sarcopenia was defined by low grip strength and low skeletal muscle mass. Study subjects were divided into the following three groups (High-, Intermediate-, and Low-Zn groups) based on the baseline serum Zn level. The impacts of serum Zn concentration on sarcopenia were examined. The median (interquartile range) serum Zn concentration for all cases was 72.85 (63.7, 81.45) μg/dL. The proportions of sarcopenia in the High-Zn, Intermediate-Zn, and Low-Zn groups were 10.75% (10/93), 11.23% (21/187), and 27.17% (25/92), respectively ( = 0.9046 (High vs. Intermediate), = 0.0007 (Intermediate vs. Low), = 0.0044 (High vs. Low), overall value = 0.0009). The median serum Zn concentrations in patients with sarcopenia, pre-sarcopenia, and control were 66.35, 73.1 and 73.8 μg/dL, respectively ( = 0.0234 (sarcopenia vs. pre-sarcopenia), = 0.2116 (pre-sarcopenia vs. control), = 0.0002 (sarcopenia vs. control), overall value = 0.0016). In the multivariate analyses of factors linked to the presence of sarcopenia, Low-Zn was an independent predictor for all cases ( = 0.0236) and LC cases ( = 0.0082). In conclusion, Zn deficiency can be an independent predictor for sarcopenia in patients with CLDs.